LSE company dividends information has been updated. You can find this is in the menu on any Quote page. ADVFN team.


Bioventix Plc

35.00 (0.96%)
Share Name Share Symbol Market Type Share ISIN Share Description
Bioventix Plc LSE:BVXP London Ordinary Share GB00B4QVDF07 ORD 5P
  Price Change % Change Share Price Shares Traded Last Trade
  35.00 0.96% 3,685.00 31,592 14:21:51
Bid Price Offer Price High Price Low Price Open Price
3,620.00 3,750.00 3,685.00 3,650.00 3,650.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Coml Physical, Biologcl Resh 11.72 7.67 147.30 25.17 191.96
Last Trade Time Trade Type Trade Size Trade Price Currency
16:19:53 O 14,779 3,665.00 GBX

Bioventix (BVXP) Latest News

Bioventix (BVXP) Discussions and Chat

Bioventix Forums and Chat

Date Time Title Posts
25/5/202312:52Bioventix - Sheep Antibodies1,494
08/11/201613:07ShareSoc Supper in Brighton-

Add a New Thread

Bioventix (BVXP) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2023-06-05 16:15:003,665.0014,779541,650.35O
2023-06-05 16:15:003,665.0014,780541,687.00O
2023-06-05 15:30:513,665.001013,701.65O
2023-06-05 15:19:543,665.001013,701.65O
2023-06-05 14:23:353,740.001686,283.20O

Bioventix (BVXP) Top Chat Posts

Top Posts
Posted at 08/5/2023 16:46 by tmfmayn
Build up of amyloid beta, which then interferes with tau, are the hallmarks of Alzheimer's as I understand. The Norwegian associate is looking at amyloid beta, with bvxp looking at tau. Comments at the agm suggested the tau data was more promising right now.
Posted at 04/5/2023 14:35 by apad
BVXP has been working on this since 2016
"We continue to await news and critical data from both of our partners in Oslo; on our secretoneurin project with CardiNor for enhancing cardiac diagnostics and on our amyloid beta project with Pre-Diagnostics in Alzheimer's diagnostics. We hope to have more news on these two projects during 2023."

The successfull Alzheimers treatment that is hitting all the mainstream news requires an early test.

Iff BVXP announces success this year it will blow the doors off.

Unfortunately one tends to get a lot older waiting for drug news.


Posted at 29/3/2023 11:00 by stepone68

That's not what I'm seeing. 6 months sales to 31-Dec-19 was £5.3m (

Then, full year to June 20 was reported as £10.3m i.e. 6 months to June 20 was £5.0m.

I could easily be wrong somewhere, but anyway, like I said it would have been a lockdown effect, and we seem to be back on track now :-)


Posted at 28/3/2023 17:09 by maddox
Excellent results - great to see the post-Covid recovery with Troponin's strong growth continuing. The quality metrics of BVXP are exceptional - so always tends to command a high p/e. BVXP's track record of paying additional special dividends is a further attraction but the 20% hike in the interim dividend shows confidence. finnCap are forecasting 9% growth for this year and next - which will be very welcome if it comes through against the worrying economic backdrop.

Whilst, still very early days, their Alzheimer's test is a very exciting prospect. It's still in the development phase, a good few years away from being commercialised and there are competitors on the same pathway - so no guaranteed success. The search for an early stage blood test for Alzheimer's is the holy grail of diagnostic testing - a potential blockbuster - so to have a horse in this race is wonderful.

Posted at 28/3/2023 14:17 by stepone68
I struggle a bit to find forecasts these days. I used to use Yahoo Finance then sharecast for a while. There were other options, but they all seem to fall by the wayside. I got some on a website called MarketScreener. Last September they were forecasting sales of 10.4 for the year ended June 22, which turned out to be 11.8m, which is quite an underestimate. At the moment they are showing 12.8 for the current year. If that turns out to be correct then the current six months would have been £6.9m, which is LESS than the same six month last year (£7.0m).

Was the 7.0m (from Jan to June last year) a fluke? It was 48% higher than the previous six months (ending Dec 2021). And it means that the 6 months just reported, was actually 15% DOWN on the previous 6.

I'd not really seen BVXP sales do this before - I mean, it's not a seasonal business, so you would think sales growth would be pretty smooth through the year.

Thinking about it, my own suggestion of 14.5m for the year would need £8.6m in H2, i.e. a near 50% rise from H1. Maybe I am being too optimistic after all.

Posted at 28/3/2023 11:25 by igbertsponk
"we are pleased to see a solid performance of our core business and look forward to this continuing over the remainder of the year"
That's pretty bullish for the traditionally VERY conservative BVXP.
On the Alzheimers test "the outlook remains exciting" is also pretty bullish.
I'm happy to remain invested and may well add on any dips. This company has never let us investors down. They signal when things won't be super and usually outperform. And the Board are bargain prices. I was pleased to see them take some reward off the table recently selling some shares.

Posted at 28/3/2023 10:52 by stepone68
Is that Turnover growth likely to continue for rest of the year? Growth had been a lot lower over the last 5 years - more like 10-15%. Is this down to Troponin?

If we get the same growth to the end of the year that would be turnover around 14.5m, Operating profit almost 10m, and EPS roughly 180p, for a P/E of 22. (Lots of assumptions in that figure, but my forecasts have always turned out to be low in previous years except for 2021).

However, the share price is largely unchanged over the last 4 years. Don't know what it would take to change that, the company is just too small for many.

What do people think is going to happen in the medium/long term here. Will the company get sold at some point? When will Peter Harrison retire? I know nobody knows the answers, but happy for some idle speculation in the meantime :-)

Posted at 27/3/2023 09:59 by melody9999
Yep - continuing to build a position - added a few more this am.

I used to go fishing - and when the river was high, I fished in different places out of the main stream.... those pools used to hold some good fish. And I use the analogy because BVXP is out of the mainstream and unaffected by current macro events. A good place to be fishing IMV but DYOR!

Posted at 29/1/2023 17:47 by tmfmayn
[Podcast] BIOVENTIX With Roland Head And Maynard Paton #BVXP

A podcast about antibody specialist BIOVENTIX with shareholders Roland Head and Maynard Paton. We talked about the wonderful longevity of diagnostic antibodies, the group's super financials, the potential for Alzheimer's testing and management's remarks at the AGM:

Show notes here:

Posted at 01/12/2022 10:23 by whilstev
Possibly explains the late trade yesterday which ignited the share price. Someone taking a stake.
Bioventix share price data is direct from the London Stock Exchange
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 |

V: D: 20230606 00:09:09